Every ADHD app that promises to “train your brain” is making the same implicit bet: that if you drill attention and memory exercises long enough, the gains show up somewhere that matters. A study just tested that bet directly, and the results are messier than either the app’s marketing or the skeptics would like.

Researchers gave adults with ADHD a randomized controlled trial of the digital cognitive training app NeuroNation MED, published in the Journal of Psychiatric Research. After 12 weeks, the app group felt noticeably sharper. Quality of life, attention, memory, all self-reported as improved. Then the researchers ran objective cognitive tests. Nothing moved.

That gap — felt better, tested the same — is the whole story. It’s also the story behind a lot of the brain-training category. Let’s get into what actually happened.

TL;DR for ADHD Brains

What	Details
Study	RCT, 77 adults (18–60) with diagnosed ADHD, University Hospital Bonn, Germany
Protocol	12 weeks, 3 sessions/week, 30–40 minutes each, 23 exercises (memory, attention, processing speed)
Self-reported result	Improved quality of life, attention, memory, language, executive function vs. control
Objective result	No measurable improvement over standard-treatment control group
Published	Moritz Bergmann et al., Journal of Psychiatric Research (2026)
Funding	Synaptikon GmbH — the app’s own developer

One-sentence verdict: NeuroNation MED made people feel like their ADHD symptoms improved without producing evidence that their cognition actually did — which is worth knowing before you pay for any brain-training app on the promise that it will.

Best for: Understanding what “clinically studied” actually means before you trust an app’s marketing copy Skip if: You’re looking for a reason to stop reading and just want the verdict — it’s above

What the Trial Actually Tested

Seventy-seven adults with diagnosed ADHD, ages 18 to 60, were enrolled through an outpatient clinic at University Hospital Bonn. Sixty completed the full protocol and were included in the final analysis. That’s not a huge sample — smaller than the 337-person attexis CBT trial I covered earlier this year — but it’s a real randomized design, not a marketing survey.

The training group used NeuroNation MED, a mobile app built by the Berlin-based company Synaptikon, for 12 weeks. Three sessions a week, 30 to 40 minutes each, working through 23 exercises that target memory, attention, and processing speed, with difficulty adapting to performance as you go. That’s a real time commitment — six to eight hours a month, sustained for three months. Not a five-minute-a-day gimmick.

The comparison group got standard ADHD treatment without the app. At the end, everyone filled out questionnaires on quality of life and perceived cognitive function, and everyone sat through objective cognitive testing — reaction time tasks, focus measures, the kind of tests that don’t care how you feel about your own performance.

The Split: What People Felt vs. What The Tests Showed

Here’s where it gets interesting, and where a lot of app marketing would prefer you stop reading.

Self-reported outcomes improved. The app group rated their quality of life higher than the control group. They reported feeling their attention, memory, language skills, and executive function had gotten better. That’s not nothing — subjective quality of life is a real outcome that matters to actual humans living actual lives.

Objective testing showed no difference. Reaction times didn’t change. Focus scores on the cognitive battery didn’t separate the app group from the control group. And core ADHD symptoms — hyperactivity, impulsivity, inattention, the stuff that actually gets diagnosed and treated — showed no meaningful improvement either.

Same people. Same 12 weeks. Two completely different stories depending on whether you asked them or tested them.

Does Brain Training Work for ADHD?

Brain training apps for ADHD reliably improve performance on the specific exercises inside the app and often produce genuine gains in how users feel about their focus and memory. What they consistently fail to demonstrate is transfer — measurable improvement on objective cognitive tests or real-world ADHD symptoms that goes beyond the app itself. The NeuroNation MED trial is a clean, recent example of that exact pattern.

This isn’t a one-off. A 2023 meta-analysis of computerized cognitive training RCTs in ADHD found the same thing across dozens of studies: trained-task gains are real, but effects on blinded, objective outcome measures shrink toward nothing. The pattern here isn’t new. What’s new is seeing it play out in a specific, currently-marketed consumer app instead of an anonymous “computerized cognitive training” category in a systematic review.

Why the Funding Source Matters Here

This part doesn’t get mentioned in most of the coverage, and it should.

The trial was funded by Synaptikon GmbH — the company that makes NeuroNation MED. That doesn’t invalidate the findings. Industry-funded trials get published in real journals all the time, and this one went through peer review at a legitimate publication.

But it’s worth sitting with the fact that the study measuring whether this app works was paid for by the people who sell it, and the result that did come back positive was the self-reported one — the outcome most vulnerable to expectation effects, placebo response, and plain old “I paid attention to my brain for 12 weeks so I assume it got better.” The outcome least vulnerable to that bias, the objective testing, came back flat.

If Synaptikon had funded a trial that found nothing at all, you probably wouldn’t be reading about it. A trial that finds “no objective change, but people liked it” is an unusually honest thing for a funder to publish. Credit where it’s due. It’s also a result that a less scrupulous write-up could spin into “clinically studied!” marketing copy without mentioning the second half of that sentence.

This Isn’t the Same Story as LumosityRx or EndeavorOTC

I’ve covered prescription digital therapeutics for ADHD before, and it’s worth being precise about why NeuroNation MED is a different animal.

LumosityRx went through FDA 510(k) clearance in the US, with clinical trial data submitted to and reviewed by a regulator before it could carry an ADHD indication. NeuroNation MED is a Class I medical device under the EU’s Medical Device Regulation — a much lower regulatory bar than FDA clearance, closer to how a bandage or a manual wheelchair gets classified than how a prescription drug does. In Germany, it’s prescribable and reimbursed by statutory health insurance as a DiGA-adjacent product. There’s no US regulatory pathway or clearance attached to it.

So don’t read “published in a peer-reviewed journal” as equivalent to “FDA-cleared based on clinical evidence.” Those are different claims with different amounts of scrutiny behind them. NeuroNation MED cleared a much lower bar, and even at that lower bar, the objective evidence came back mixed.

Where This Leaves the Rest of the Brain-Training Category

If you’ve looked into neurofeedback devices for ADHD, this will sound familiar. Same pattern: users report feeling more focused, objective measures against active controls are weaker and less consistent. The BMJ’s umbrella review of ADHD interventions rates most cognitive training and neurofeedback approaches as low-certainty evidence for a reason. This trial doesn’t change that ranking. It adds one more clean data point to it.

Compare that to what a digital CBT trial for ADHD found around the same time: a –5.0 point drop on a validated symptom scale, comparable to face-to-face therapy benchmarks, with objective functioning measures moving too. That’s a genuinely different evidence tier from what NeuroNation MED produced. Both are “digital ADHD interventions.” They are not equally supported.

So Should You Use a Brain-Training App?

Here’s my honest take, not the marketing version.

If quality of life improves for you while using something like NeuroNation MED — if the sessions make you feel more in control of your day — that’s a real benefit, even if a cognitive test can’t detect it. Feeling better is not nothing. I’m not going to tell you that a subjective improvement doesn’t count just because a reaction-time task didn’t pick it up.

What I won’t do is tell you this trial shows the app “improves ADHD cognition,” because it doesn’t show that. If your reason for spending six to eight hours a month on brain-training exercises is a belief that it will measurably sharpen your working memory or attention, this specific evidence doesn’t back that belief up. Spend the time if the experience itself is worth it to you. Don’t spend it as a substitute for interventions with a stronger track record, and don’t let “clinically studied” language talk you into treating it as equivalent to medication or CBT.

For working memory specifically, if that’s the symptom you’re actually trying to solve for, the working memory apps built as external storage rather than training tools tend to have a more direct, immediate payoff — they don’t ask your brain to get better, they just do the remembering for you.

The Bottom Line

Seventy-seven adults, 12 weeks, a real randomized design, and a result that split cleanly down the middle: subjective yes, objective no. That’s not a scandal. It’s what a lot of cognitive training research has quietly shown for years, now attached to a specific app you can currently download.

Feeling sharper matters. It’s just not the same claim as being sharper, and an app that wants your $10 a month or your prescriber’s signature should have to earn the second claim separately from the first.

---

The trial, “Effects of a novel individualized digital cognitive training on ADHD characteristics, quality of life, and cognitive functioning in adults with ADHD,” was published by Moritz Bergmann et al. in the Journal of Psychiatric Research in 2026, and covered by Medical Xpress and PsyPost on July 30, 2026. The study was funded by Synaptikon GmbH, the developer of NeuroNation MED.